{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.28","upperLimit":"6.17","value":"5.72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"}],"units":"Participants"}],"description":"The PK parameter estimates from the current analysis are listed together with the population PK model estimates. The Vss is the sum of central volume of distribution (V1) + peripheral volume of distribution (V2).","dispersionType":"95% Confidence Interval","groups":[{"description":"75 milligrams per meter squared (mg/m\\^2) doxorubicin administered intravenously (IV) on day 1 of each 21 day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21 day cycle until documented progressive disease (PD) or discontinuation for any other reason.","id":"OG000","title":"Doxorubicin + Olaratumab"}],"paramType":"MEAN","populationDescription":"All randomized participants who had received at least one dose of study drug and had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Cycle 1- 9: Day 1 and 8; Predose, 5 Minutes Post dose and then every other cycle and follow-up (30 Days)","title":"PK: Volume of Distribution at Steady State (Vss) of Olaratumab: Mean Parameter Estimate","type":"SECONDARY","unitOfMeasure":"Liter (L)"}